$CANB Can B Corp. Executes Joint Venture with Prim
Post# of 266
(Total Views: 425)
Posted On: 03/03/2022 9:28:59 AM
$CANB Can B Corp. Executes Joint Venture with PrimeX Making its CBD Products Available in Brazil
https://www.newmediawire.com/news/can-b-corp-...il-6202891
Enables Access to the 4th Largest Pharmaceutical Market in the World and its 210 Million Consumers
Hicksville, NY - (NewMediaWire) - March 03, 2022 - Can B Corp. (OTCQB:CANB) ("Can B'' or the "Company"
, a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, is pleased to announce its formation of a joint venture with PrimeX, a marketing, sales, and distribution company, for its CBD products in Brazil.
PrimeX has a contract with Biocase Brasil to produce CBD products for the Brazilian market. Biocase is a company focused on: local distribution, an intensive education program for doctors (MDs), production of oils, capsules, and creams through local facilities, and the development of a biotech laboratory for cannabis testing and extraction.
Biocase Brasil has a strong network of doctors in Brazil and provides education, research, products development, and tests for the Brazilian market. Brazil relies on medical clinical trials to test CBD products for new categories, such as beauty, veterinary use, and food, before regulation permits the distribution to pharmacies and online sales. Biocase Brasil patients also have access to prescriptions and Anvisa licenses!
PrimeX services 120,000 retailers in Brazil, which includes markets, pharmacies, and bodegas, a country that recently approved the sale of CBD products in pharmacies. The joint venture will utilize PrimeX's existing distribution relationships in Brazil.
The largest country in South America, Brazil is the fourth biggest pharmaceutical market in the world. The Brazilian National Health System is one of the largest public health systems in the world. In 2019, Brazil had 114,352 community pharmacies (76.8% privately owned), which represent the first point of access to healthcare in Brazil due to their wide distribution.
Medical cannabis and CBD are expected to surge in Brazil with the passage of new legislation, with estimates that the sector could reach $4.7 billion in sales in the next three years. Up until recently, CBD in Brazil was permitted only for medical use with authorization from the National Sanitary Surveillance Agency. Regulations are in place for medical cannabis and hemp opening up a market of 210 million consumers.
There are only a few companies in Brazil - CBD Vida being one - selling CBD-based pharmaceuticals through prescription and medical reports. Only a handful of importers have established distribution in Brazil, including GW Pharmaceuticals, Biocase Brazil, which sells its Sativex CBD-based medicine in pharmacies, and Biocase sells Allandiol Full and Broad.
Mario Lacourt, PrimeX's Chief Executive Officer, stated, "We are very excited to roll out Can B's CBD products in Brazil. After careful consideration, Biocase Brasil chose Can B for its high standards of manufacturing and processing and quality products. The CBD category in Brazil is ever-expanding to new categories and we are very well-positioned to distribute Can B's products to the majority of pharmacies, markets, and bodegas in Brazil."
Marco Alfonsi, Can B's Chief Executive Officer, stated, "This is a significant expansion milestone for our company as Brazil is the fourth biggest pharmaceutical market in the world and we now have access to this huge market via PrimeX. The CBD opportunity in Brazil is emerging with recently passed legislation that is opening up the market to its 210 million people. We look forward to working closely with PrimeX and utilizing its existing relationships with pharmacies in Brazil."
https://www.newmediawire.com/news/can-b-corp-...il-6202891
Enables Access to the 4th Largest Pharmaceutical Market in the World and its 210 Million Consumers
Hicksville, NY - (NewMediaWire) - March 03, 2022 - Can B Corp. (OTCQB:CANB) ("Can B'' or the "Company"
, a health and wellness company specializing in developing, producing, and selling hemp-derived cannabinoid products, is pleased to announce its formation of a joint venture with PrimeX, a marketing, sales, and distribution company, for its CBD products in Brazil. PrimeX has a contract with Biocase Brasil to produce CBD products for the Brazilian market. Biocase is a company focused on: local distribution, an intensive education program for doctors (MDs), production of oils, capsules, and creams through local facilities, and the development of a biotech laboratory for cannabis testing and extraction.
Biocase Brasil has a strong network of doctors in Brazil and provides education, research, products development, and tests for the Brazilian market. Brazil relies on medical clinical trials to test CBD products for new categories, such as beauty, veterinary use, and food, before regulation permits the distribution to pharmacies and online sales. Biocase Brasil patients also have access to prescriptions and Anvisa licenses!
PrimeX services 120,000 retailers in Brazil, which includes markets, pharmacies, and bodegas, a country that recently approved the sale of CBD products in pharmacies. The joint venture will utilize PrimeX's existing distribution relationships in Brazil.
The largest country in South America, Brazil is the fourth biggest pharmaceutical market in the world. The Brazilian National Health System is one of the largest public health systems in the world. In 2019, Brazil had 114,352 community pharmacies (76.8% privately owned), which represent the first point of access to healthcare in Brazil due to their wide distribution.
Medical cannabis and CBD are expected to surge in Brazil with the passage of new legislation, with estimates that the sector could reach $4.7 billion in sales in the next three years. Up until recently, CBD in Brazil was permitted only for medical use with authorization from the National Sanitary Surveillance Agency. Regulations are in place for medical cannabis and hemp opening up a market of 210 million consumers.
There are only a few companies in Brazil - CBD Vida being one - selling CBD-based pharmaceuticals through prescription and medical reports. Only a handful of importers have established distribution in Brazil, including GW Pharmaceuticals, Biocase Brazil, which sells its Sativex CBD-based medicine in pharmacies, and Biocase sells Allandiol Full and Broad.
Mario Lacourt, PrimeX's Chief Executive Officer, stated, "We are very excited to roll out Can B's CBD products in Brazil. After careful consideration, Biocase Brasil chose Can B for its high standards of manufacturing and processing and quality products. The CBD category in Brazil is ever-expanding to new categories and we are very well-positioned to distribute Can B's products to the majority of pharmacies, markets, and bodegas in Brazil."
Marco Alfonsi, Can B's Chief Executive Officer, stated, "This is a significant expansion milestone for our company as Brazil is the fourth biggest pharmaceutical market in the world and we now have access to this huge market via PrimeX. The CBD opportunity in Brazil is emerging with recently passed legislation that is opening up the market to its 210 million people. We look forward to working closely with PrimeX and utilizing its existing relationships with pharmacies in Brazil."
(0)
(0)CAN B CORP. (CANB) Stock Research Links
Scroll down for more posts ▼